Aptevo Therapeutics Inc.
APVOAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Piper Sandler | maintain | Overweight | May 12, 2022 |
| Roth Capital | maintain | Buy | May 27, 2021 |
| PiperJaffray | maintain | Overweight | Nov 25, 2020 |
| Roth Capital | maintain | Buy | Nov 25, 2020 |
| Piper Sandler | maintain | Overweight | Nov 10, 2020 |
| Roth Capital | maintain | Buy | Apr 11, 2018 |
| PiperJaffray | maintain | Overweight | Sep 9, 2016 |
Earnings History
Next report: Apr 1, 2027 · EPS est. $-3.14| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-5.31 | $-6.01 | — | — |
| May 13, 2026 | $-6.41 | $-5.60 | — | — |
| Mar 20, 2026 | $1684.47 | $-8.09 | — | — |
| Nov 6, 2025 | $-40.11 | $-37.59 | — | — |
| Aug 11, 2025 | $-151.20 | $-83.20 | — | — |
| May 15, 2025 | $-1579.14 | $-4.21 | — | — |
| Mar 4, 2025 | $-3218.40 | $-7.75 | — | — |
| Nov 7, 2024 | $-6255.86 | $-7428.84 | — | — |
News
Next generation multispecific technology designed to coordinate innate and adaptive immune activity within the tumor microenvironment SEATTLE, WA / ACCESS Newswire / October 14, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel bispecific and multispecific immunotherapies for the treatment of cancer, today announced that the Company will highlight its multispecific platform in a presentation at the Society for Immunotherapy of Cance…
Aptevo Therapeutics Inc. (NASDAQ: APVO - Get Free Report) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totaling 187,942 shares, a growth of 59.0% from the August 31st total of 118,188 shares. Based on an average daily volume of 336,643 shares,
Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human Testing Trispecifics Combine Three Complementary Cancer-Fighting Functions in One Molecule, Enabling a Coordinated Approach to Recognizing Cancer, Activating Immune Cells and Addressing Tumor Defenses SEATTLE, WA / ACCESS Newswire / September 24, 2026 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel m…
Aptevo Therapeutics Inc. (NASDAQ: APVO - Get Free Report)'s share price crossed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $3.22 and traded as low as $1.73. Aptevo Therapeutics shares last traded at $1.84, with a volume of 423,830 shares. Wall Street Analyst Weigh In Separately,
Aptevo Therapeutics Inc. (NASDAQ:APVO) announced that its lead candidate mipletamig achieved a 93% clinical benefit rate when administered as a triplet therapy to frontline acute myeloid leukemia patients carrying TP53 mutations.
Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success SEATTLE, WA / ACCESS Newswire / September 3, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced a 93% clinical benefit rate with its mipletamig triplet in evaluable frontline acute myeloid leukemia (AML) patients with TP53 mutations, one of the most difficult-to-treat form…
Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2 Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology Pipeline Non-Dilutive Grant Funding Advances APVO451 and Validates Trispecific Solid Tumor Strategy Strategic Niowave Collaboration Opens a New Radiopharmaceutical Therapeutic Development Opportunity SEATTLE, WA / ACCESS Newswire / August 14, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology compan…
SEATTLE, WA / ACCESS Newswire / August 13, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today closed its previously announced warrant inducement transaction with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holders have exercised in full for cash their Existing Warrants to purchase up to an aggregate of 254,922 shar…
SEATTLE, WA / ACCESS Newswire / August 12, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced it has entered into warrant inducement letter agreements with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holders have agreed to exercise in full for cash their Existing Warrants to purchase up to an aggregate of…